Aprea Therapeutics, Inc. · NASDAQ:APRE

Aprea Therapeutics — Investor Presentation (August 2026)

26 slides from Aprea Therapeutics's investor presentation, August 2026

  1. Slide 1: A clinical-stage precision medicine oncology company

    A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers August 2026 1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical

  3. Slide 3: Aprea Therapeutics: One Critical Pathway - Multiple Targets

    Aprea Therapeutics (NASDAQ: APRE) Synthetic Lethality Aprea Precision Medicine One Critical Pathway - Multiple Targets Positioned at the forefront of synthetic lethality and precision medicine Transition from broad, toxic chemotherapy Targeted Oncology to potentially safer, precision-guided targeted

  4. Slide 4: Robust DDR Development Pipeline and Corporate Milestones

    Robust DDR Development Pipeline and Corporate Milestones 2025-2028 Accomplished and anticipated milestones 2025 2026 2027 2028 H2 H1 H2 H1 H2 H1 H2 Financing $30 Million Raise Safety & Safety & Open Backfill Interim Safety & Complete Dose Efficacy Data Efficacy Data Cohorts Efficacy Presentation* Es

  5. Slide 5: Strong Drug Development and Commercial Expertise

    Strong Drug Development and Commercial Expertise Experienced team in synthetic lethality and targeted therapy Management Oren Gilad, PhD John P. Hamill Eugene Kennedy, MD Ze’ev Weiss, CPA, Mike Carleton, PhD Brian Wiley President and CEO SVP and CFO Chief Medical Advisor BSc Translational Medicine S

  6. Slide 6: WEE1 Inhibitor APR-1051: Clinical Proof-Of-Concept

    WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept 6 6 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

  7. Slide 7: WEE1 Has Emerged as a Therapeutic Target of Significant Industry Interest

    WEE1 Has Emerged as a Therapeutic Target of Significant Industry Interest Clinically validated, prior WEE1 inhibitors have been challenged by narrow therapeutic windows Aprea is applying key insights to advance APR-1051 as a potentially best-in-class WEE1 inhibitor Program Clinical Limitations Strat

  8. Slide 8: ACESOT-1051: Phase 1 Study Design

    ACESOT-1051: Phase 1 Study Design Multi-center, open-label Phase 1 single-agent dose escalation and dose selection optimization Part 1 Dose escalation Select 2 Part 2 Dose selection optimization up to 100 patients dose levels Up to 80 patients Dose level 11 Selected 500mg Eligible patients dose 1 R

  9. Slide 9: APR-1051 Summary of Duration of Treatment

    APR-1051 Summary of Duration of Treatment (n=28 for all dose levels) Data Cutoff: May 6, 2026 02-004 9 01-015 13 APR-1051 once-daily dose 01-013 44 300 mg Not shown: 01-012 84 50 mg (n=6) 220 mg 30 mg (n=1) 03-012 58 ✼ 150 mg 20 mg (n=1) 01-011 140 100 mg 10 mg (n=1) Study patient 03-011 12 70 mg 01

  10. Slide 10: Treatment-related AEs in Patients Treated with APR-1051

    Treatment-related AEs in Patients Treated with APR-1051 (N=28) Data Cutoff: May 6, 2026 MedDRA Preferred Term APR-1051 All dose levels (N=28) Treatment-related AEs, n (%)a All Grades Grade ≥ 3b Nausea 10 (35.7) 0 (0) Fatigue 4 (14.3) 0 (0) Vomiting 3 (10.7) 0 (0) Alanine aminotransferase increased 1

  11. Slide 11: Confirmed Partial Response in Patient 01-011

    Confirmed Partial Response in Patient 01-011 220mg QD – Currently on treatment Demographics: 63-year-old Black Female Site: MD Anderson Cancer Center Diagnosis: Uterine carcinosarcoma Key Mutations: PPP2R1A Treatment History (4 prior lines) • Line 1: Carboplatin + Paclitaxel → 126 days, PD • Line 2:

  12. Slide 12: Disease Control Observed in Early Patient Outcomes

    Disease Control Observed in Early Patient Outcomes APR-1051 shows preliminary evidence of disease control in rectal cancer with mutated FBXW7 100 mg Cohort Case Report Stable disease maintained for 178 days in patient with FBXW7 mutation (100 mg QD) (elected to stop study participation) Patient: 86-

  13. Slide 13: Disease Control Observed in Early Patient Outcomes

    Disease Control Observed in Early Patient Outcomes APR-1051 shows preliminary evidence of disease control in HPV+ head and neck cancer 70 mg Cohort Case Report Stable disease maintained for 223 days in patient 01-005 HPV+ head and neck cancer (70 mg QD) (PD) Patient: 62-year-old White Male Diagnosis

  14. Slide 14: Biomarker Defined Registration Path

    Biomarker Defined Registration Path Preliminary signals of monotherapy activity across cohorts in genomically defined tumors including uterine cancer, endometrial cancer, CRC and HNSCC Clinical Activity by Indication and Biomarker Path to Registrational Cohort Biomarker / Altered Clinical Activity i

  15. Slide 15: APR-1051: Potentially Differentiated WEE1 Inhibitor

    APR-1051: Potentially Differentiated WEE1 Inhibitor Pre-Clinical 15 15 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

  16. Slide 16: APR-1051: Potentially Best-in-Class WEE1 Inhibitor

    APR-1051: Potentially Best-in-Class WEE1 Inhibitor Structurally differentiated: high potency, limited off-target inhibition design compared to other molecules APR-1051 is based on a different molecular structure than AZD-1775 and ZN-c3 (not an analogue) Undisclosed AstraZeneca Zentalis Aprea Adavose

  17. Slide 17: APR-1051: Potentially Best-in-Class WEE1 Inhibitor

    APR-1051: Potentially Best-in-Class WEE1 Inhibitor Potent inhibitor of WEE1 Does not substantially inhibit structurally and functionally related PLK1, PLK2 or PLK3 On-target WEE1 potency1 Important difference in off-target inhibition between APR-1051 and ZN-c31 WEE1 IC50 Determination PLK1 IC50 Dete

  18. Slide 18: PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors

    PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors1 Minimal PLK1 co-inhibition enhances therapeutic window for APR-1051 APR-1051 APR-1051 75 nM 400 nM GSK-PLKi BI-PLKi 333 nM 111 nM 333 nM 111 nM 333 nM 111 nM 333 nM 111 nM 37 nM 37 nM 37 nM 37 nM 1 µM 1 µM 1 µM 1 µM NT NT Evidence of DNA damage

  19. Slide 19: PLK1 Suppression Associated with Sepsis-Induced Loss of Intestinal Barrier Function

    Studies Show PLK1 Suppression is Associated with Sepsis-Induced Loss of Intestinal Barrier Function 1 PLK1 protects against sepsis-induced intestinal barrier dysfunction, Cao et al, Scientific Reports (2018). 2 PLK1 protects intestinal barrier function in sepsis: A translational research, Cao et al,

  20. Slide 20: APR-1051 Showed Preclinical Activity in Combination Across Multiple Cancer Models

    APR-1051 Showed Preclinical Activity in Combination with Chemo, IO and ATRi Across Multiple Cancer Models APR-1051 suggests synergistic potential preclinically with standard oncology agents Chemotherapy Immuno-oncology DDR combination Vehicle rea ed Aprea ATRi 30 mg/kg QD AP Aprea WEE1i 30 mg/kg QD

  21. Slide 21: APR-1051 WEE1 Summary

    APR-1051 WEE1 Summary A next-generation WEE1i with the potential to deliver meaningful clinical benefit and durable value 1 Clinically validated target • WEE1 inhibitors have shown promising activity in genomically defined tumors • Competitor programs constrained by low therapeutic window 2 APR-1051

  22. Slide 22: Intellectual Property Portfolio, Financial Summary & Capitalization, Investment Highlights

    Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights 22 22 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

  23. Slide 23: Robust Global Intellectual Property Protection

    Robust Global Intellectual Property Protection Family 1 Ataxia Telangiectasia and • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015 Rad3-Related (ATR) Protein • Patents granted in AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, HK. Kinase Inhibitors •

  24. Slide 24: Financial Summary and Capitalization

    Aprea Therapeutics (NASDAQ: APRE) Financial Summary and Capitalization Cash and Equivalents of ~$41.2M as of June 30, 2026 $30.0M in gross proceeds raised in private placement that closed on March 31, 2026 Common Equivalents Securities as of August 12, 2026 Preferred Stock (as converted) 15,596 Comm

  25. Slide 25: Investment Highlights

    Investment Highlights Technology developed by pioneers in synthetic lethality • Management with strong drug development and commercial expertise • Focused on addressing unmet needs for patients with biomarker defined cancers Highly potent and selective design, potential best in class inhibitors • Di

  26. Slide 26: Aprea Therapeutics (NASDAQ: APRE)

    Aprea Therapeutics (NASDAQ: APRE) 26 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

Aprea Therapeutics — Investor Presentation (August 2026) on 6ix